In February 2024, Gritstone bio reduced its workforce by approximately 40% to reduce costs and preserve capital. The reduction primarily impacted employees associated with vaccine manufacturing and clinical infectious disease operations, who were not active in the ongoing Phase 2 study of GRANITE, Gritstone’s personalized cancer vaccine. The reduction occurred approximately two weeks following the previously announced delay of the proposed CORAL Phase 2b study, which resulted in Gritstone not receiving external funding it previously anticipated beginning in 1Q 2024, associated with the initiation of the study.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GRTS:
- Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
- Gritstone Oncology (GRTS) Q4 Earnings Cheat Sheet
- Gritstone announces 40% reduction in workforce
- Apollo Global upgraded, Dell initiated: Wall Street’s top analyst calls
- Gritstone initiated with an Outperform at JMP Securities